{"id":"NCT00960440","sponsor":"Pfizer","briefTitle":"Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors","officialTitle":"Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2009-08-17","resultsPosted":"2013-01-10","lastUpdate":"2018-12-19"},"enrollment":399,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":["double-blind, placebo-controlled phase"]},{"type":"DRUG","name":"CP-690,550","otherNames":["double-blind, extension phase"]},{"type":"DRUG","name":"Placebo","otherNames":["double-blind, placebo-controlled phase"]},{"type":"DRUG","name":"CP-690,550","otherNames":["double-blind, extension phase"]}],"arms":[{"label":"Sequence 1","type":"EXPERIMENTAL"},{"label":"Sequence 2","type":"EXPERIMENTAL"},{"label":"Sequence 3","type":"PLACEBO_COMPARATOR"},{"label":"Sequence 4","type":"PLACEBO_COMPARATOR"}],"summary":"This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3","timeFrame":"Month 3","effectByArm":[{"arm":"CP-690,550 5 mg","deltaMin":41.67,"sd":null},{"arm":"CP-690,550 10 mg","deltaMin":48.12,"sd":null},{"arm":"Placebo","deltaMin":24.43,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"0.0024"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":92,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","France","Germany","Ireland","Italy","Puerto Rico","South Korea","Spain","Taiwan"]},"refs":{"pmids":["39192350","38958913","37925660","37453736","36931693","36814062","36601090","36600185","36526796","35577477","34921355","34870800","33127856","33059710","32816215","30177460","29949132","28941219","28143815","27889300","26275429","25186034","25047021","23294500"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921032&StudyName=Phase%203%2C%20Randomized%2C%20Double-Blind%2C%20Placebo-Controlled%20Study%20Of%20The%20Safety%20And%20Efficacy%20Of%202%20Doses%20Of%20CP-690%2C550%20In%20Patients%20With%20Active%20Rheumatoid%20Arthritis%20On%20Background%20Methotrexate%20With%20Inadequate%20Response%20To%20TNF%20Inhibitors"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":133},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Nausea","Diarrhoea","Urinary tract infection"]}}